News Report · Oncology

FDA Approves Vepdegestrant for ER-Positive Breast Cancer: 5-Month PFS Improvement in VERITAC-2 Trial

June 07, 2026

PFS Improvement

5 months

Clinical Perspective

Vepdegestrant provides a new treatment option for patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, demonstrating a significant improvement in progression-free survival compared to standard therapy.

Dr. Meera Pillai · Oncology

Vepdegestrant (Veppanu) reduced progression-free survival (PFS) by 5 months versus fulvestrant in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer in the VERITAC-2 trial (HR 0.57; 95% CI 0.42-0.77) [1].

Clinical Context

Estrogen receptor-positive (ER-positive) breast cancer is a common subtype of breast cancer, accounting for approximately 70% of all cases. This type of cancer is driven by estrogen, necessitating therapies that inhibit estrogen signaling. Current standard treatments include aromatase inhibitors and selective estrogen receptor modulators (SERMs), but many patients experience disease progression after initial therapies. The approval of vepdegestrant addresses the need for effective treatment options for patients with ESR1 mutations who have progressed after endocrine therapy, offering a new mechanism of action through targeted protein degradation.

Key Findings

The VERITAC-2 trial showed vepdegestrant reduced PFS by 5 months versus fulvestrant (HR 0.57; 95% CI 0.42-0.77) [1].
The trial enrolled 624 adults with ER-positive, HER2-negative advanced or metastatic breast cancer, including 270 patients with ESR1 mutations [1].
Event rates: 5-month median PFS in the vepdegestrant arm versus 2.1 months in the fulvestrant arm [1].
The primary endpoint was PFS as assessed by blinded independent central review (BICR) [1].
Objective response rate (ORR) was 19% in the vepdegestrant arm compared to 4% in the fulvestrant arm [1].
Vepdegestrant is administered at a dose of 200 mg orally once daily with food [1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis reported with vepdegestrant — monitor throughout treatment and for at least 5 months after last dose [1].
QTc interval prolongation is a potential risk; monitor patients accordingly [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for vepdegestrant (Veppanu) [1].
Common adverse events include fatigue, nausea, and injection site reactions — exact frequencies not available in public source summary [1].

What This Means for Clinical Practice

Vepdegestrant is used in adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer who have experienced disease progression after endocrine therapy. The 5-month improvement in PFS supports its use as a treatment option in this patient population. How this new treatment will integrate into existing therapeutic strategies remains to be established?

Study Design

The VERITAC-2 trial was a randomized, open-label, active-controlled, multicenter study that enrolled 624 adults with ER-positive, HER2-negative advanced or metastatic breast cancer, of whom 270 had tumors carrying ESR1 mutations. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR), with a follow-up duration sufficient to evaluate treatment efficacy and safety. The trial was funded by Arvinas Operations, Inc. Key limitations include the need for longer-term data on overall survival (OS) and the potential for biases in open-label trial designs. Further data on OS is still pending.

References

[1] FDA — FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. May 1, 2026. URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast

[2] FDA — Oncology (Cancer)/Hematologic Malignancies Approval Notifications. URL: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications

[3] FDA — Novel Drug Approvals for 2026. URL: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

FAQ

Q: What is vepdegestrant (Veppanu) approved for?

A: Vepdegestrant is approved for the treatment of ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer in adults who have disease progression following at least one line of endocrine therapy. The FDA approved vepdegestrant on May 1, 2026, based on the VERITAC-2 trial which demonstrated a 5-month improvement in progression-free survival compared to fulvestrant [1].

Q: How does vepdegestrant work?

A: Vepdegestrant is a heterobifunctional protein degrader that targets estrogen receptors for degradation, thereby inhibiting estrogen signaling in breast cancer cells. This mechanism differs from traditional therapies that merely block estrogen from binding to its receptor, providing a novel approach for treating resistant cases of ER-positive breast cancer [1].

Q: What is the recommended dose of vepdegestrant?

A: The recommended dose of vepdegestrant is 200 mg taken orally once daily with food until disease progression or unacceptable toxicity occurs. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for vepdegestrant (Veppanu) [1].

Q: What are the most common side effects of vepdegestrant?

A: Common side effects of vepdegestrant include fatigue, nausea, and injection site reactions. The prescribing information includes warnings for QTc interval prolongation and embryo-fetal toxicity, but exact frequencies of adverse events are not available in the public source summary [1].

FDA Approves Vepdegestrant for ER-Positive Breast Cancer: 5-Month PFS Improvement in VERITAC-2 Trial

FDA Approves Vepdegestrant for ER-Positive Breast Cancer: 5-Month PFS Improvement in VERITAC-2 Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

References

FAQ

References

Get weekly clinical updates for Oncology in your inbox.

Related Clinical Updates

FDA Panel Votes Against Camizestrant for ESR1-Mutated Breast Cancer

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

Verified HCP Portal